Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inactivated convalescent plasma
- Development stage
- Phase 2
- Lead developer
- National Blood Center Foundation
- Administration
- Intravenous
01
Overview
Inactivated convalescent plasma (National Blood Center Foundation/Hemolife) is a biologic therapy consisting of plasma collected from recovered COVID-19 patients. The plasma is treated with riboflavin (vitamin B2) and ultraviolet (UV) light using the Mirasol Pathogen Reduction Technology system to inactivate potential viral particles, including SARS-CoV-2, while preserving the functional integrity of neutralizing antibodies. These antibodies target the SARS-CoV-2 spike protein and its receptor-binding domain (RBD), thereby providing passive immunity and inhibiting viral attachment to host cells. This therapeutic approach has been evaluated in Phase 2 clinical trials for hospitalized COVID-19 patients presenting with severe conditions such as pneumonia, acute respiratory distress syndrome (ARDS), or sepsis.
- Other names
- inactivated convalescent plasma-National Blood Center Foundation, Hemolife-COVID-19riboflavin and UV-inactivated convalescent plasmaMirasol-treated convalescent plasma
02
Targets
S1-NTD (SARS-CoV-2 spike S1 N-terminal domain)RBD (SARS-CoV-2 spike receptor-binding domain)S2 (SARS-CoV-2 spike S2 subunit)
Beyond the preview
Go deeper on inactivated convalescent plasma.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inactivated convalescent plasma.